An early clinical trial with autologous CD33-CAR T cells in patients with refractory AML did not show significant clinical responses, although CAR-T cell activity was noted in two of three patients, as evidenced by cytokine release syndrome (CRS) [31]. The gene discussed is CD33; the disease is acute myeloid leukemia.